GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magle Chemoswed Holding AB (OSTO:MAGLE) » Definitions » EV-to-EBIT

Magle Chemoswed Holding AB (OSTO:MAGLE) EV-to-EBIT : 23.18 (As of Jun. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Magle Chemoswed Holding AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Magle Chemoswed Holding AB's Enterprise Value is kr426.6 Mil. Magle Chemoswed Holding AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr18.4 Mil. Therefore, Magle Chemoswed Holding AB's EV-to-EBIT for today is 23.18.

The historical rank and industry rank for Magle Chemoswed Holding AB's EV-to-EBIT or its related term are showing as below:

OSTO:MAGLE' s EV-to-EBIT Range Over the Past 10 Years
Min: 15.18   Med: 27.93   Max: 250.09
Current: 23.19

During the past 6 years, the highest EV-to-EBIT of Magle Chemoswed Holding AB was 250.09. The lowest was 15.18. And the median was 27.93.

OSTO:MAGLE's EV-to-EBIT is ranked worse than
70.38% of 422 companies
in the Biotechnology industry
Industry Median: 9.705 vs OSTO:MAGLE: 23.19

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Magle Chemoswed Holding AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr413.6 Mil. Magle Chemoswed Holding AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr18.4 Mil. Magle Chemoswed Holding AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.45%.


Magle Chemoswed Holding AB EV-to-EBIT Historical Data

The historical data trend for Magle Chemoswed Holding AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magle Chemoswed Holding AB EV-to-EBIT Chart

Magle Chemoswed Holding AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - 155.11 54.78 25.79 17.78

Magle Chemoswed Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.58 27.00 32.39 17.78 22.48

Competitive Comparison of Magle Chemoswed Holding AB's EV-to-EBIT

For the Biotechnology subindustry, Magle Chemoswed Holding AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magle Chemoswed Holding AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magle Chemoswed Holding AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Magle Chemoswed Holding AB's EV-to-EBIT falls into.



Magle Chemoswed Holding AB EV-to-EBIT Calculation

Magle Chemoswed Holding AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=426.598/18.403
=23.18

Magle Chemoswed Holding AB's current Enterprise Value is kr426.6 Mil.
Magle Chemoswed Holding AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr18.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Magle Chemoswed Holding AB  (OSTO:MAGLE) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Magle Chemoswed Holding AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=18.403/413.638
=4.45 %

Magle Chemoswed Holding AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr413.6 Mil.
Magle Chemoswed Holding AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr18.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Magle Chemoswed Holding AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Magle Chemoswed Holding AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Magle Chemoswed Holding AB (OSTO:MAGLE) Business Description

Traded in Other Exchanges
N/A
Address
Agneslundsvagen 27, Malmo, SWE, 21215
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.

Magle Chemoswed Holding AB (OSTO:MAGLE) Headlines

No Headlines